SG10202102897PA - Compositions and methods for the depletion of cd137+ cells - Google Patents

Compositions and methods for the depletion of cd137+ cells

Info

Publication number
SG10202102897PA
SG10202102897PA SG10202102897PA SG10202102897PA SG10202102897PA SG 10202102897P A SG10202102897P A SG 10202102897PA SG 10202102897P A SG10202102897P A SG 10202102897PA SG 10202102897P A SG10202102897P A SG 10202102897PA SG 10202102897P A SG10202102897P A SG 10202102897PA
Authority
SG
Singapore
Prior art keywords
depletion
compositions
cells
methods
Prior art date
Application number
SG10202102897PA
Inventor
Adam Hartigan
Anthony Boitano
Michael Cooke
Megan D Hoban
Rahul Palchaudhuri
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of SG10202102897PA publication Critical patent/SG10202102897PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10202102897PA 2017-01-20 2018-01-19 Compositions and methods for the depletion of cd137+ cells SG10202102897PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448741P 2017-01-20 2017-01-20
US201762595977P 2017-12-07 2017-12-07

Publications (1)

Publication Number Publication Date
SG10202102897PA true SG10202102897PA (en) 2021-04-29

Family

ID=62907802

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202102897PA SG10202102897PA (en) 2017-01-20 2018-01-19 Compositions and methods for the depletion of cd137+ cells
SG11201906319XA SG11201906319XA (en) 2017-01-20 2018-01-19 Compositions and methods for the depletion of cd137+ cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201906319XA SG11201906319XA (en) 2017-01-20 2018-01-19 Compositions and methods for the depletion of cd137+ cells

Country Status (14)

Country Link
US (3) US10576161B2 (en)
EP (1) EP3571230A4 (en)
JP (2) JP7256744B2 (en)
KR (1) KR20190107097A (en)
CN (1) CN110461876B (en)
AU (1) AU2018209452A1 (en)
BR (1) BR112019014991A2 (en)
CA (1) CA3049501A1 (en)
IL (1) IL268058B2 (en)
MA (1) MA47331A (en)
MX (2) MX2019008205A (en)
SG (2) SG10202102897PA (en)
TW (1) TWI825007B (en)
WO (1) WO2018134787A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019522050A (en) 2016-06-17 2019-08-08 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Compositions and methods for cell depletion
IL268058B2 (en) * 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137plus cells
CN112739340A (en) * 2018-07-23 2021-04-30 美真达治疗公司 Use of anti-CD 5 Antibody Drug Conjugates (ADCs) in allogeneic cell therapy
CA3107019A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy
CA3107378A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy
SG11202107045PA (en) 2019-02-13 2021-07-29 Beam Therapeutics Inc Compositions and methods for treating hemoglobinopathies
US20230135930A1 (en) 2019-04-24 2023-05-04 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
AU2020276500A1 (en) * 2019-05-10 2021-12-16 Lyvgen Biopharma Holdings Limited Humanized anti-CD137 antibodies and uses thereof
JP2022536094A (en) * 2019-06-05 2022-08-12 マジェンタ セラピューティクス インコーポレイテッド Therapies that remove T cells
US20230017979A1 (en) * 2019-08-29 2023-01-19 Beam Therapeutics Inc. Compositions and methods for non-toxic conditioning
US20230242658A1 (en) * 2020-06-30 2023-08-03 Nona Biosciences (Suzhou) Co., Ltd. 4-1bb-binding protein and use thereof
CN116635045A (en) * 2020-12-28 2023-08-22 广州辑因医疗科技有限公司 Culture medium composition for amplifying and maintaining self-renewal capacity and differentiation potential of HSCs and application thereof
CN114369581B (en) * 2021-12-30 2023-10-20 杭州医学院 Recombinant adenovirus with anti-tumor immunity function, preparation method and application

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5451575A (en) 1988-02-19 1995-09-19 J. W. Broadbent Nominees Pty., Ltd. Method of treating liver dysfunction with 24-R scymnol
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US5786457A (en) 1989-02-23 1998-07-28 Colorado State University Research Foundation Hormone-nuclease compounds and method for regulating hormone related diseases
WO1990009799A1 (en) 1989-02-23 1990-09-07 Colorado State University Research Foundation GnRH ANALOGS FOR DESTROYING GONADOTROPHS
US5273738A (en) 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
JP3213314B2 (en) 1991-04-05 2001-10-02 ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン Monoclonal antibodies against stem cell factor receptor
WO1993015751A1 (en) 1992-02-14 1993-08-19 Merck & Co., Inc. CHIMERIC TOXINS BINDING TO THE GnRH RECEPTOR
CA2161771C (en) 1993-04-30 2009-01-13 L. David Tomei Methods of identifying potentially therapeutically effective agents and cell strains for use therein
WO1994026290A1 (en) 1993-05-07 1994-11-24 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6024957A (en) 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
ATE454449T1 (en) 1993-09-16 2010-01-15 Univ Indiana Res & Tech Corp HUMAN RECEPTOR H4-1BB
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
AU5369996A (en) 1995-03-23 1996-10-08 Indiana University Foundation Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
DE69624436T2 (en) 1995-04-08 2003-08-28 Lg Chemical Ltd HUMANER 4-1BB SPECIFIC HUMAN ANTIBODY AND THIS PRODUCING CELL LINE
DE19600589C1 (en) 1996-01-10 1997-01-16 Univ Eberhard Karls Antibody A3C6E2
DE19608769C1 (en) 1996-03-07 1997-04-10 Univ Eberhard Karls Monoclonal antibody BV10A4H2 specific for human FLT3/FLK2 receptor
US5874240A (en) 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
JP2001502325A (en) 1996-10-11 2001-02-20 ブリストル―マイヤーズ・スクイブ・カンパニー Methods and compositions for immunomodulation
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
DK0973550T3 (en) 1997-04-11 2003-02-10 Searle & Co Antagonistic anti-AVB3 integrin antibodies
DE19727814C1 (en) 1997-06-30 1998-10-01 Univ Eberhard Karls Monoclonal antibody specific for human tyrosine kinase receptor protein
KR20000034847A (en) 1998-11-17 2000-06-26 성재갑 Humanized Antibody Specific for Human 4-1BB Molecule and Pharmaceutical Composition Comprising Same
US20030096976A1 (en) 1998-11-17 2003-05-22 Hong Hyo Jeong Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
US6339062B1 (en) 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US6831071B2 (en) 1999-04-08 2004-12-14 Pavel Sergeev Synthesis of biologically active compounds in cells
US6159443A (en) 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
AUPQ014699A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
US7217811B2 (en) 2000-10-18 2007-05-15 The United States Of America As Represented By The Department Of Health And Human Services Human gene critical to fertility
JP2004536555A (en) 2000-11-03 2004-12-09 ダナ ファーバー キャンサー インスティテュート Methods and compositions for diagnosing cancer susceptibility and defective DNA repair mechanisms and treatments
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
CA2467597A1 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
US7183385B2 (en) 2002-02-20 2007-02-27 Cell Signaling Technology, Inc. Phospho-specific antibodies to Flt3 and uses thereof
US20030232369A1 (en) 2002-04-17 2003-12-18 Bushnell David A. Molecular structure of RNA polymerase II
US20030223989A1 (en) 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
DE10219866A1 (en) 2002-05-03 2003-11-20 Isolde Riede-Kainrath Treatment and prevention of tumors, using compounds that modulate expression of switch genes or genes for RNA polymerase II, or activity of their products
JP2006500921A (en) 2002-07-30 2006-01-12 ブリストル−マイヤーズ　スクイブ　カンパニー Humanized antibody against human 4-1BB
AU2002953073A0 (en) 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
US20060121030A1 (en) 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
KR100500283B1 (en) * 2003-03-25 2005-07-11 이뮤노믹스 주식회사 Humanized Monoclonal Polypeptide Specific for Human 4-1BB Molecule and Pharmaceutical Composition Comprising Same
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US20060014197A1 (en) 2004-07-15 2006-01-19 Wisconsin Alumni Research Foundation In vivo screening methods for identifying inhibitors of RNA polymerases
EP1778224B1 (en) 2004-07-19 2014-03-26 The Johns-Hopkins University Flt3 inhibitors for immune suppression
EP1661584A1 (en) 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20060182744A1 (en) 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
US20080019905A9 (en) 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
KR100694508B1 (en) 2005-05-24 2007-03-13 울산대학교 산학협력단 A composition comprising HBBK4 antibody for the treatment of cancer and the immunotherapic method for treating cancer using thereby
WO2007092196A2 (en) 2006-01-27 2007-08-16 Cellerant Therapeutics, Inc. Compositions and methods for treating myeloid proliferative disorders
US20090220529A1 (en) 2006-03-10 2009-09-03 Diatos, S.A. Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
ATE521366T1 (en) 2006-05-27 2011-09-15 Faulstich Heinz Dr APPLICATION OF AMATOXIN CONJUGATES AND PHALLOTOXIN CONJUGATES WITH MACROMOLECLES FOR CANCER THERAPY AND THERAPY OF INFLAMMATION
MX2008015132A (en) 2006-05-30 2008-12-10 Genentech Inc Antibodies and immunoconjugates and uses therefor.
WO2008031056A2 (en) 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008036374A2 (en) 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
EP3255061B1 (en) 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
EP2609932B1 (en) 2006-12-01 2022-02-02 Seagen Inc. Variant target binding agents and uses thereof
US20100093008A1 (en) 2007-03-02 2010-04-15 Cell Signaling Technology, Inc. Phospho-specific antibodies to flt3 (tyr969) and uses thereof
KR20080107050A (en) * 2007-06-05 2008-12-10 울산대학교 산학협력단 Pharmaceutical composition for preventing or treating chronic graft-versus-host disease comprising anti-cd137 monoclonal antibody
AU2008268432B2 (en) 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9518097B2 (en) 2007-11-09 2016-12-13 Board Of Trustees Of Michigan State University Identification and use of genes encoding amatoxin and phallotoxin
US20110229460A1 (en) 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
AR071891A1 (en) 2008-05-30 2010-07-21 Imclone Llc ANTI-FLT3 HUMAN ANTIBODIES (THIROSINE KINASE 3 RECEPTOR HUMAN FMS TYPE)
LT3192529T (en) * 2009-04-08 2020-06-25 Faulstich, Heinz, Dr. Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
SG174328A1 (en) 2009-04-08 2011-10-28 Deutsches Krebsforsch Amatoxin-armed target-binding moieties for the treatment of cancer
US20120076722A1 (en) 2009-05-14 2012-03-29 University Of Maryland, Baltimore Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
HUE028629T2 (en) 2009-12-23 2016-12-28 Synimmune Gmbh Anti-flt3 antibodies and methods of using the same
EP2521782B1 (en) 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists for the treatment or the prevention of pain disorders
KR20110085038A (en) * 2010-01-19 2011-07-27 울산대학교 산학협력단 Method for selective depletion of cd137 positive cells using anti-cd137-antibody and toxin complex
BR112012026801B8 (en) 2010-04-15 2021-05-25 Medimmune Ltd targeted pyrrolobenzodiazepine conjugates, pharmaceutical composition, use thereof for treatment of a proliferative or autoimmune disease and drug binding
EP4098272A3 (en) 2010-07-13 2023-03-08 University of Rhode Island Board of Trustees Compositions comprising a ph-sensitive membrane insertion polipeptide
PL2614082T3 (en) 2010-09-09 2019-02-28 Pfizer Inc. 4-1bb binding molecules
EP2436398B1 (en) 2010-09-30 2013-01-23 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkers
EP2656079A2 (en) 2010-12-20 2013-10-30 Universiteit Gent Crystal structure of flt3 ligand-receptor complex
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
BR112013024395B1 (en) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center ADOPTIVE COMPOSITIONS OF CELL IMMUNOTHERAPY AND METHOD FOR MANUFACTURING SUCH COMPOSITION
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
EP3536708A1 (en) 2011-04-19 2019-09-11 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CN103648530B (en) 2011-05-08 2017-02-08 乐高化学生物科学股份有限公司 Protein-active agent conjugates and method for preparing the same
AR086044A1 (en) 2011-05-12 2013-11-13 Imclone Llc ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME
US20140234320A1 (en) * 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
AU2012322613B2 (en) 2011-10-14 2016-04-21 Medimmune Limited Pyrrolobenzodiazepines and targeted conjugates
CA2850264C (en) 2011-10-14 2019-11-05 Spirogen Sarl Pyrrolobenzodiazepines
RU2657758C2 (en) 2011-12-22 2018-06-15 Иеда Рисеч Энд Девелопмент Ко. Лтд. Combination therapy for stable and long-term transplant engraftment
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
WO2013173393A1 (en) 2012-05-15 2013-11-21 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
KR102268351B1 (en) 2012-07-25 2021-06-22 셀덱스 쎄라퓨틱스, 인크. Anti-kit antibodies and uses thereof
WO2014043403A1 (en) 2012-09-12 2014-03-20 Agensys, Inc. Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
SG10201702387YA (en) 2012-09-24 2017-04-27 Medimmune Ltd Cell lines
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
CA2887727A1 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
CA2908227A1 (en) 2013-02-28 2014-09-04 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
EP3514178A1 (en) 2013-03-15 2019-07-24 Novartis AG Antibody drug conjugates
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
MD20180107A2 (en) * 2013-03-18 2019-06-30 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
WO2014197854A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
AU2014299561B2 (en) 2013-06-24 2017-06-08 Ablbio Antibody-drug conjugate having improved stability and use thereof
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
FR3008408B1 (en) 2013-07-11 2018-03-09 Mc Saf NOVEL ANTIBODY-MEDICAMENT CONJUGATES AND THEIR USE IN THERAPY
WO2015005431A1 (en) 2013-07-12 2015-01-15 石原産業株式会社 Composition for transferring gene to cell
JP6441949B6 (en) 2013-11-05 2019-01-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Human neutralizing anti-KIT antibody and use thereof
KR20150055655A (en) 2013-11-13 2015-05-22 삼성디스플레이 주식회사 Apparatus for cleaning a substrate
BR112016020065A2 (en) 2014-03-12 2018-02-20 Novartis Ag specific sites to modify antibodies to make immunoconjugates
EP3148592A2 (en) 2014-06-02 2017-04-05 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
ES2785551T3 (en) 2014-06-30 2020-10-07 Glykos Finland Oy Saccharide derivative of a toxic payload and its conjugates with antibodies
JP6692343B2 (en) 2014-08-01 2020-05-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Anti-CD45RC antibody for use as a drug
EP3822364B1 (en) 2014-08-26 2023-05-10 The Board of Trustees of the Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
WO2016036334A1 (en) 2014-09-03 2016-03-10 Şahi̇n Yücel Voltametric methods to determine alpha-amanitin and phalloidin
CN106922129B (en) 2014-10-01 2024-02-20 免疫医疗有限责任公司 Methods of conjugating polypeptides
US20190209704A1 (en) 2014-10-20 2019-07-11 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions and methods of use
EP3215519A1 (en) 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
KR20170083095A (en) 2014-11-11 2017-07-17 아뮤닉스 오퍼레이팅 인코포레이티드 Targeted xten conjugate compositions and methods of making same
EP3026060A1 (en) 2014-11-26 2016-06-01 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for CD45R0
SG10202003171TA (en) 2015-01-08 2020-05-28 BioNTech SE Agonistic tnf receptor binding agents
US20160220687A1 (en) 2015-02-02 2016-08-04 National Guard Health Affairs Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer
EP3878861A1 (en) 2015-02-16 2021-09-15 Lonza Ltd. Cl and/or ch1 mutated antibodies for drug conjugation
EP3265565B1 (en) 2015-03-04 2020-08-12 Board of Regents, The University of Texas System Methods of treating cancer harboring hemizygous loss of tp53
CN107614010A (en) 2015-03-09 2018-01-19 艾更斯司股份有限公司 It is bound to the antibody drug conjugates (ADC) of FLT3 albumen
US10842882B2 (en) 2015-03-09 2020-11-24 Heidelberg Pharma Gmbh Amatoxin-antibody conjugates
US20180318285A1 (en) 2015-03-10 2018-11-08 President And Fellows Of Harvard College Methods for treatment of autism spectrum disorders
BR112017021536A2 (en) 2015-04-06 2018-07-03 Harvard College compositions and methods for nonmyeloablative conditioning
US10683506B2 (en) 2015-04-10 2020-06-16 The Methodist Hospital System CD117 ligand-drug conjugates for targeted cancer therapy
US20180110871A1 (en) 2015-04-17 2018-04-26 Endocyte, Inc. Dual disulfide drug conjugates
RU2017138083A (en) 2015-05-18 2019-06-18 Универсидади Ду Порту APPLICATION OF POLIMIXIN AS ANTIDOTE IN AMATOXIN POISONING
US10806808B2 (en) 2015-05-22 2020-10-20 Memorial Sloan Kettering Cancer Center Systems and methods for determining optimum patient-specific antibody dose for tumor targeting
JP6948708B2 (en) 2015-06-19 2021-10-13 センチュリオン バイオファーマ コーポレイション Delivery system for controlled drug release
US10961308B2 (en) 2015-06-29 2021-03-30 The General Hospital Corporation Embigin inhibition for promotion of hematopoietic stem and progenitor cell expansion
EP3322449A1 (en) 2015-07-16 2018-05-23 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins
WO2017023753A1 (en) 2015-07-31 2017-02-09 University Of Florida Research Foundation, Inc. Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
WO2017051249A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
EP3365448A1 (en) 2015-10-23 2018-08-29 Apogenix AG Single-chain cd137-receptor agonist proteins
WO2017089607A1 (en) 2015-11-27 2017-06-01 Heidelberg Pharma Gmbh Derivatives of gamma-amanitin
WO2016059622A2 (en) * 2016-02-04 2016-04-21 Suzhou M-Conj Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
SG11201807652SA (en) 2016-04-20 2018-10-30 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
EP3452492A1 (en) 2016-05-05 2019-03-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
CN115645544A (en) 2016-05-31 2023-01-31 索伦托药业有限公司 Antibody drug conjugates with amatoxin derivatives as drugs
SG10202100726XA (en) 2016-06-17 2021-02-25 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells
AU2017380099A1 (en) 2016-12-23 2019-06-13 Heidelberg Pharma Research Gmbh Amanitin antibody conjugates
IL268058B2 (en) * 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137plus cells
EP3661938A1 (en) 2017-08-07 2020-06-10 Heidelberg Pharma Research GmbH Novel method for synthesizing amanitins

Also Published As

Publication number Publication date
SG11201906319XA (en) 2019-08-27
BR112019014991A2 (en) 2020-04-07
JP2020506176A (en) 2020-02-27
MX2022011546A (en) 2022-10-18
KR20190107097A (en) 2019-09-18
AU2018209452A1 (en) 2019-07-18
IL268058B2 (en) 2023-09-01
US10434185B2 (en) 2019-10-08
WO2018134787A3 (en) 2018-10-04
TW201833134A (en) 2018-09-16
JP7256744B2 (en) 2023-04-12
EP3571230A2 (en) 2019-11-27
US20200289664A1 (en) 2020-09-17
JP2023093500A (en) 2023-07-04
TWI825007B (en) 2023-12-11
CN110461876B (en) 2024-05-17
CN110461876A (en) 2019-11-15
EP3571230A4 (en) 2020-12-16
IL268058B1 (en) 2023-05-01
US10576161B2 (en) 2020-03-03
US20190076548A1 (en) 2019-03-14
MX2019008205A (en) 2020-01-23
IL268058A (en) 2019-09-26
CA3049501A1 (en) 2018-07-26
WO2018134787A2 (en) 2018-07-26
MA47331A (en) 2019-11-27
US20180289832A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
SG10202102897PA (en) Compositions and methods for the depletion of cd137+ cells
IL263743A (en) Compositions and methods for the depletion of cells
IL263744A (en) Compositions and methods for the depletion of cd117 plus cells
SG11202003280SA (en) Compositions and methods for the depletion of cd117+ cells
IL282735A (en) Compositions and methods for t cell engineering
IL275263A (en) Compositions and methods for inhibiting t cell exhaustion
EP3700540A4 (en) Compositions and methods for the depletion of cd117+ cells
IL263896A (en) T cell compositions for immunotherapy
IL280659A (en) Processes for generating engineered cells and compositions thereof
IL269334A (en) Improved t cell compositions and methods
EP3331582A4 (en) Methods and compositions for treating cells for transplant
IL282596A (en) Compositions for the elimination of senescent cells
IL255480B (en) Compositions comprising mesenchymal stem cells and uses thereof
SG11202004294XA (en) Compositions and methods for the depletion of cd5+ cells
SG11202004192XA (en) Compositions and methods for the depletion of cd2+ cells
IL271022A (en) Compositions and methods for providing cell replacement therapy
IL286776A (en) Compositions and methods for preparing t cell compositions and uses thereof
IL278201A (en) Methods and compositions of cytotoxic t cell depletion
IL263341A (en) Stem cell material, compositions, and methods of use
IL282160A (en) Compositions and methods for transfecting cells
EP3122333A4 (en) Cell free compositions for cellular restoration and methods of making and using same
PL3601588T3 (en) Phenotypic characterization of cells
GB202014449D0 (en) Compositions and methods of cell attachment
IL260253A (en) Methods and compositions for detaching adherent cells
IL290109A (en) Cells for improved immunotherapy and uses thereof